Managinq attention deficit/hyperactivity disorder: Unmet needs and future directions

Archives of Disease in Childhood

Volumn 90, Issue SUPPL. 1, 2005, Pages

  Steer, C R ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; CLONIDINE DERIVATIVE; EQUASYM XL; FLUOXETINE; GUANFACINE; LOFEXIDINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; CENTRAL STIMULANT AGENT;

ABDOMINAL PAIN; AGITATION; ANAMNESIS; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COMORBIDITY; CRYING; DISEASE EXACERBATION; DIZZINESS; DRUG DEPENDENCE; EDUCATION; GENERAL PRACTICE; GROWTH RETARDATION; HEADACHE; HIGH RISK POPULATION; HUMAN; INSOMNIA; IRRITABILITY; MEDICAL RESEARCH; OPPOSITIONAL DEFIANT DISORDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RATING SCALE; REVIEW; SCHOOL; SEIZURE; SIDE EFFECT; SOCIAL SUPPORT; SYMPTOMATOLOGY; TIC; WEIGHT GAIN; ADOLESCENT; AMBULATORY CARE; CHILD; COUNSELING; DIET THERAPY; FEMALE; MALE; METHODOLOGY; PRESCHOOL CHILD; SCHOOL HEALTH SERVICE;

ADOLESCENT; AMBULATORY CARE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COUNSELING; FEMALE; HUMANS; MALE; SCHOOL HEALTH SERVICES; SOCIAL SUPPORT;

EID: 13744257053     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2004.059352     Document Type: Review

References (110)

1. The MTA Cooperative Group. A 14-month randomised clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86.
2. Pliszka SR. Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management. Pediatr Drugs 2003;5:741-50.
3. Scottish Intercollegiate Guidelines Network SIGN. No 52. Attention deficit and hyperkinetic disorders in children and young people. A National Clinical Guideline, June, 2001.
4. National Instituts of Clinical Excellence (NICE). Technology Appraisal Guidance No 13. Guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood, October, 2000.
5. Klasen H, Goodman R. Parents and GPs at cross purposes over hyperactivity: a qualitative study of possible barriers to treatment. Br J Gen Pract 2000;50:199-202.
6. Ball C. Attention deficit hyperactivity disorder (ADHD) and the use of methylphenidate: a survey of the views of general practitioners. Psychiatric Bull 2001;25:301-4.
7. Sayal K, Taylor E, Beecham J, et al. Pathways to care in children at risk of attention deficit hyperactivity disorder. Br J Psychiatry 2002;181:43-8.
8. Thapar A, Thapar A. Is primary care ready to take on attention deficit hyperactivity disorder? BMC Fam Pract 2002;3:7.
9. Anastopoulos AD, Shelton TL, DuPaul GJ, et al. Parent training for attention-deficit hyperactivity disorder: its impact on parent functioning. J Abnormal Child Psychol 1993;21:581-96.
10. Pelham WE Jr, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol 1998;27:190-205.
11. Barkley RA. Psychosocial treatments for attention-deficit/hyperactivity disorder in children J Clin Psychiatry 2002;63(Suppl. 12):36-43.
12. Abikoff H. Cognitive training in ADHD children: less to it than meets the eye. J Learn Disabil 1991;24:205-9.
13. Jensen PS. Fact versus fancy concerning the multimodal treatment study for attention deficit hyperactivity disorder. Can J Psychiatry 1999;44:975-80.
14. Pelham WE. The NIMH multimodal treatment study for attention deficit hyperactivity disorder: just say yes to drugs alone? Can J Psychiatry 1999;44:981-90.
15. Taylor E. Development of clinical services for attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 1999;56:1097-9.
16. Corkum P, Rimer P, Schachar R. Parental knowledge of attention deficit hyperactivity disorder and opinions of treatment options: impact on enrolment and adherence to a 12-month trial. Can J Psychiatry 1999;44:1043-8.
17. Klein RG, Abikoff H, Hechtman L, et al. Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2004;43:792-801.
18. Abikoff H, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:802-11.
19. Hechtman L, Abikoff H, Klein RG, et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:812-19.
20. Abikoff H, Hechtman L, Klein RG, et al. Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:820-9.
21. Hechtman L, Abikoff H, Klein RG, et al. Children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment: impact an parental practices. J Am Acad Child Adolesc Psychiatry 2004;43:830-8.
22. Johnston C, Mash EJ. Families of children with ADHD: review and recommendations for future research. Clin Child Fam Psychol Rev 2001;4:183-207.
23. National Institutes of Health Consensus Statement. Diagnosis and treatment of attention deficit hyperactivity disorder, November 16-18, 1998.
24. Gaub M, Carlson CL. Gender differences in ADHD: a meta-analysis and critical review. J Am Acad Child Adolesc Psychiatry 1997;36:1036-45.
25. Hinshaw SP. Preadolescent girls with attention-deficit/hyperactivity disorder: I. Background characteristics, comorbidity, cognitive and social functioning, and parenting practices. J Consult Clin Psychol 2002;70:1086-98.
26. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409-32.
27. Miller A, et al. A review of therapies for attention deficit hyperactivity disorder. Ottawa: Canadian Coordinating Office for Health Technology Assessment, (CCOHTA), 1999.
28. McMaster University. The treatment of attention deficit hyperactivity disorder. Agency for Healthcare Research and Quality. Evidence Based report/Technology Assessment No 11. AHRQ. Pub No 00-E005. Rockville, MD, 1999.
29. Barkley RA. Hyperactive boys: stimulant effects on mother-child interactions. J Child Psychol Psychiatry 1989;30:379-90.
30. Gadow KD, Nolan EE, Sverd J, et al. Methylphenidate in aggressive-hyperactive boys: 1. Effects on peer aggression in public school settings. J Am Acad Child Adolesc Psychiatry 1990;29:710-18.
31. Charach A, Ickowicz A, Schachar R. Stimulant treatment over 5 years: adherence, effectiveness and adverse effects. J Am Acad Child Adolesc Psychiatry 2004;43:559-67.
32. National Institutes of Mental Health. Multimodal treatment study of attention deficit hyperactivity disorder. Follow up at 24 month outcomes of treatment strategies for attention deficit hyperactivity disorder. Pediatrics 2004;113:754-62.
33. Taylor E, Dopfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):I7-30.
34. Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systematic placebo-controlled evaluation. Pediatrics 1990;86:184-92.
35. Campbell Daley K. Update on attention deficit hyperactivity disorder. Curr Opin Pediatrics 2004;16:217-20.
36. Joshi SV. Attention deficit hyperactivity disorder, growth deficits, and relationships to psychostimulant use. Pediatr Rev 2002;23:67-8.
37. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder. Issues and approaches for improvement. CNS Drugs 2003;17:117-31.
38. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. Proof of concept and proof of product studies. Arch Gen Psychiatry 2003;60:204-11.
39. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant treatment of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003;111:179-85.
40. BBC News. Public inquiry call over drug. 2 July 2001. Available at: http://news.bbc.co.uk/1/hi/ScoHand/1417080.stm.
41. Diller LH. The Ritalin Wars continue. West J Med 2000;173:366-7.
42. Barkley RA. International Consensus Statement on attention deficit hyperactivity disorder. Clin Child Fam Psychol Rev 2002;5:89-111.
43. Timimi S, Taylor E. ADHD is best understood as a cultural construct. Br J Psychiatry 2004;184:8-9.
44. Double DB, Taylor E. Meanings and causes in ADHD. Br J Psychiatry 2004;184:453-4.
45. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:e105.
46. Wolraich ML, Greenhill LL, Pelham W, et al. Randomised, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001;108:883-92.
47. Greenhill LL, Findling RL, Swanson JM, the ADHD Study Group. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit hyperactivity disorder. Pediatrics 2002;109:e39.
48. Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study) Pediatrics 2004;113:e206-16.
49. Sleator EK, Ullmann RK, von Neumann A. How do hyperactive children feel about taking stimulants and will they tell the doctor? Clin Pediatr 1982;21:474-9.
50. Pliszka SR. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr 2003;8:253-8.
51. Coghill D. Evidence-based psychopharmacology for children and adolescents. Curr Opin Psychiatry 2002;15:361-8.
52. Jureidini JN, Doecke CJ, Mansfield PR, et al. Efficacy and safety of antidepressants for children and adolescents. Clinical Review. BMJ 2004;328:879-83.
53. Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med 2004;350:1489-91.
54. McCracken JT, McGough J, Shah B. Risperidone in children with autism and serious behaviour problems. N Engl J Med 2002;347:314-21.
55. Pappadopulos E, Macintyre Ii JC, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY) Part II. J Am Acad Child Adolesc Psychiatry 2003;42:145-61.
56. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette Syndrome. Neurology 2003;60:1130-5.
57. King B, Zwi K, Nunn K, et al. Use of risperidone in a paediatric population: an observational study. J Paediatr Child Health 2003;39:523-7.
58. Gilbert DL, Batterson JR, Sethuraman G, et al. Tic reduction with risperidone versus pimozide in a randomised, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004;43:206-14.
59. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Cnild Adolesc Psychiatry 2000;39:509-16.
60. Kelsey D, Summer C, Casat C, et al. Once-daily atomoxetine in childhood ADHD; continuous symptom relief. Poster presented at the 50th American Academy of Child and Adolescent Psychiatry meeting, Miami, Florida, 14-19 October, 2003.
61. Kratochvil CJ, Vaughan BS, Harrington MJ, et al. Atomoxetine: A selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin Pharmacother 2003;4:1165-74.
62. Michelson D, Faries D, Wernicke J, et al. & the Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficity/hyperactivity disorder: a randomised, placebo-controlled, dose response study. Pediatrics, 2001;108:l-9.
63. Dulcan M. Practice Parameters for the assessment and treatment of children, adolescents and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36(Suppl 10):85S-121S.
64. Wender EH. The food additive-free diet in the treatment of behavior disorders: a review. J Dev Behav Pediatr 1986;7:35-42.
65. Mattes JA. The Feingold Diet: a current reappraisal. J team Disabil 1983;16:319-23.
66. Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind placebo controlled artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of pre-school children. Arch Dis Child 2004;89:506-11.
67. Eigenmann PA, Haenggeli CA. Food colourings and preservatives-allergy and hyperactivity. Lancet 2004;364:823-4.
68. Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Ped 2003;24:4-8.
69. DuPaul GJ, McGoey KE, Eckert TL, et al. Preschool children with attention-deficit/hyperoctivity disorder; impairments in behavioural, social and school functioning. J Am Acad Child Adolesc Psychiatry 2001;40:508-15.
70. Short EJ, Manos MJ, Findling RL, et al. A prospective study of stimulant response in preschool children: insights from ROC analyses. J Am Acad Child Adolesc Psychiatry 2004;43:251-9.
71. Dunn DW, Austin JK, Caffrey HM, et al. A prospective study of teachers' ratings of behavior problems in children with new-onset seizures. Epilepsy Behav 2003;4:26-35.
72. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsies in children and young people. SIGN, 2005 (in press).
73. Berkley RA. Diagnosis and treatment of attention deficit hyperoctivity disorder. Long-term course, adult outcome and comorbid disorders. In: NIH Consensus Development Conference, Bethesda, MD, 16-18 November, 1998:57-60.
74. Vollmer S. ADHD: it's not just in children. Family Practice Recertification 1998;20:45-68.
75. Corkum P, Tannock R, Moldofsky H. Sleep disturbances in children with attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1998;37:637-46.
76. Mick E, Biederman J, Jetton J, et al. Sleep disturbances associated with attention-deficit hyperactivity disorder: the impact of psychiatric comorbidity and phormacotherapy. J Child Adolesc Pharmacol 2000;10:223-31.
77. Gruber R, Sadeh A, Raviv A. Instability of sleep patterns in children with attention-deficit/hyperactivity disorder. JAm Acad Child Adolesc Psychiatry 2000;39:495-501.
78. Owens JA, Maxim R, Nobile C, et al. Parental ond self report of sleep in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2000;154:549-55.
79. O'Brien LM, Ivanenko A, Crabtree VM, et al. Sleep disturbances in children with attention-deficit/hyperactivity disorder. Pediatr Res 2003;54:237-43.
80. O'Brien LM, Ivanenko A, Crabtree VM, et al. The effects of stimulants on sleep characteristics in children with attention-deficit/hyperactivity disorder. Sleep Med 2003;4:309-16.
81. Reed MD, Findling RL. Overview of current management of sleep disturbances in children: I. Pharmacotherapy. Curr Ther Res Clin Exp 2000;63(Suppl B):B18-37.
82. Stores GA. Clinical guide to sleep disorders in children and adolescents, Cambridge; Cambridge University Press, 2001.
83. Stores G. Medication for sleep-wake disorders. Arch Dis Child 2003;88:899-903.
84. Meltzer U, Mindell JA. Non-pharmacological treatments for pediatric sleepiness. Pediatr Clin North Am 2004;51:135-51.
85. Conners KC. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999;46:857-70.
86. Collett BR, Ohan JL, Myers KM. Ten year review of rating scales. V: Scales assessing attention-deficit/hyperactivity disorder, J Am Acad Child Adolesc Psychiatry 2003;42:1015-37.
87. DuPaul GJ. ADHD Rating Scale: Check lists, norms, and clinical interpretation. New York: Guildford Press, 1998.
88. Faries DE, Yalcin I, Harder D, et al. Validation of the ADHD Rating Scole as a clinician administered and scored instrument. J Atten Dis 2001;5:107-15.
89. Conners CK, Sitarenios G, Parker JD, et al. The Revised Conners' Parent Rating Scale (CPRS-R). Factor structure, reliability and criterion validity. J Abn Child Psychol 1998;26:257-68.
90. Conners CK, Sitarenios G, Parker JD, et al. Revision and restandardisation of the Conners' Teacher Rating Scale (CTRS): factor structure, reliability and criterion validity. J Aim Child Psychol 1998;26:279-91.
91. Goodman R. The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiatry 1997;38:581-6.
92. Landgraf JM, et al. The Child Health Questionnaire (CHQ): A user's manual. Boston: The Health Institute, New England Medical Center, 1996.
93. Riley AW. Child Health and Illness Profile-Child Edition (CHIP-CE). Parent reported form. Baltimore: The Johns Hopkins University Press, 2001.
94. Harter S. Manual for self perception profile for children. Denver, CO: University of Denver, 1985.
95. Sutton V, Sumner C, Allen AJ, et al. Validity, reliability, ond responsiveness of the DPREMB-R scale for ADHD. Poster presented at the 50th American Academy of Child and Adolescent Psychiatry, Miami, Florida, 14-19 October, 2003.
96. Hill P, Taylor E. An auditable protocol for treating ADHD. Arch Dis Child 2001;84:404-9.
97. Rothenberger A, Danckaerts M, Dopfner M, et al. EINAQ-a European educational initiative on attention-deficit hyperactivity disorder and associated problems. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):131-5.
98. Steingard R, Biederman J, Spencer T, et al. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 1993;32:350-3.
99. Wilens TE, Biederman J, Spencer T. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994;33:424-6.
100. Singer HS, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette's Syndrome: a double-blind, plocebo-controlled trial with clonidine and desipramine. Pediatrics 1995;95:74-81.
101. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:50-4.
102. Horrigan JP, Barnhill LJ. Guanfacine treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 1995;5:215-23.
103. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in attention deficit hyperactivity disorder comorbid with oggressive oppositional defiont disorder or conduct disorder, Clin Pediatrics (Phila) 2000;39:15-25.
104. Tourette's Syndrome Study Group. Treatment of attention deficit hyperactivity disorder in children with tics: a randomised, controlled trial. Neurology 2002;58:527-36.
105. Niederhofer H, Staffen W, Mair A. A placebo-controlled trial of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. J Psychopharmacol 2003;17:113-19.
106. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:649-57.
107. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention-deficit hyperactivity disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996;35:1314-42.
108. Barrickman L, Noyes R, Kuperman S, et al. Treatment of attention deficit hyperactivity disorder with nuoxetine: a preliminary study. J Am Acad Child Adolesc Psychiatry 1991;30:762-7.
109. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit hyperactivity disorder and comorbid depressive disorders. J Child Adolesc Psychopharmacol 1993;3:1-10.
110. Olvera RL, Pliszka SR, Luh J, et al. An open trial of venlafaxine in the treatment of attention-deficit hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 1996;6:241-50.